CDER appointment
This article was originally published in The Tan Sheet
Executive Summary
Douglas Throckmorton, MD, is appointed to the permanent post of CDER Deputy Director, FDA's Center for Drug Evaluation & Research announces Sept. 22. Throckmorton has been acting in the position since May 2004 (1"The Tan Sheet" April 19, 2004, p. 9). Throckmorton started at FDA in 1997 as a medical officer in the Division of Cardiovascular & Renal Drug Products, became deputy director of the division in 2000 and was appointed division director in 2002. "Doug's medical, regulatory and leadership skills make him an outstanding addition to CDER's senior management team and I am honored that he has agreed to continue as my deputy," CDER Director Stephen Galson states...
You may also be interested in...
FDA Cardio-Renal Head Throckmorton Named CDER Acting Deputy
FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.